Grow With Us

For over 100 years, a group of vibrant individuals we call Otsuka-people have shared the mission of creating new products for better health worldwide. We live by our purpose: to defy limitation, so that others can too.

Current Openings

Remote

Vice President, Customer Engagement

Position Summary
The Vice President, Customer Engagement Operations is a strategic leader responsible for driving the operational backbone of Otsuka’s commercial organization. 
This role…

Apply

Remote-Sales

Associate Director, Digital Health Engagement Partner (Sales) IA, MO, MI, OH

Otsuka Precision Health is a health experience company that brings personalized care within reach through products and services for mental and physical well-being. Combining the power of human…

Apply

Ohio

Associate Director, Digital Health Engagement Partner (Sales) Il, IN, MI, OH

Otsuka Precision Health is a health experience company that brings personalized care within reach through products and services for mental and physical well-being. Combining the power of human…

Apply

Discover more careers.

Open positions

Awards

#72 in Fortune Best Workplaces for Millennials™ 2024

#14 in Fortune Best Workplaces in New York™ 2024

GPTW_2024_Certification_Badge

Great Place To Work® Certified

Benefits

Our comprehensive benefits package invests in each employee’s health, well-being, financial future, and educational development.

Health

Medical, dental, vision, and
prescription coverage

Access to telehealth 24 hours/day

Health advocacy services

Life insurance and accidental death & dismemberment benefits

Short- and long-term disability benefits

Well-being

Comprehensive wellness offerings, including a fitness reimbursement
program, nutrition resources, and a
digital mindfulness program

Legal and identity protection plan

Generous paid time off allocation and 10 days of paid holidays

Family

Parental, adoption, and family
caregiver leave programs

Range of medical plan options offering flexibility to meet each family's needs

Financial

Best-in-class 401(k) retirement
savings plan, providing a matching contribution of up to 10 percent of
base salary

Personalized financial counseling, to help with tax planning strategies, education funding, purchasing a home, and estate planning

Education

Industry-leading tuition
reimbursement program

Year-round development offerings
and workshops

Opportunities for new challenges via internal mobility

Industry expert keynote speaker sessions

Monthly career and development eNewsletters

Work anniversary and achievement awards

See how we value diversity.

DIVERSITY, EQUITY & INCLUSION

Our Sales Development Program

Otsuka has a field sales development program, ReadyNow, for those interested in pharmaceutical sales, but who may not have any previous experience in it. While a bachelor’s degree from a college or university and 2-5 years of postgraduate business experience is expected, a lack of sales experience does not have to be a barrier to start. All that is needed is a willingness to learn about our business and a desire to become immersed in Otsuka’s culture and values. Email us at [email protected] for more information about the ReadyNow program.

Our Sales Development Program

Some Of Our Specialist
Areas Include:

Business

Commercial strategy

Digital medicine

Finance and
administration

Information technology

Marketing &
communications

Market access

Medical communications

Sales

Project management

Technical operations

Regulatory

Ethics and compliance

Government affairs

Legal affairs

Regulatory affairs

Clinical & Research

Biometrics

Biostatistics

Clinical development

Clinical outsourcing

Clinical pharmacology

Clinical programming

Clinical safety
and pharmacovigilance

Drug discovery 

Medical affairs

Our Unique Culture

There are 2 core principles, based on our Japanese heritage, by which all Otsuka-people have lived for nearly a century. Today, they continue to serve as the foundation of our culture, embodying who we are and how we will achieve our goals.

jissho

(JIS-SHOH) Actualization

Achievement, completion, and the discovery of truth

Otsuka-people are encouraged to push themselves far beyond expectations. To dream the impossible and make it a reality. By living the principles of jissho, individuals and teams can achieve unprecedented outcomes that ultimately lead to greater responsibility.

sozosei

(SOH-ZOH-SAY) Creativity

Pursuing what only Otsuka is capable of conceiving and achieving

Sozosei gives Otsuka-people permission to do what's never been done and can only be done by Otsuka. Every day is a new chance to invent and to create so that we can provide answers to medical needs that have yet to be addressed.

See our open positions.

Careers

Who We Are

Curious

We live to learn and discover. That’s why we never stop asking questions: Why? How? What if? Our inquisitive nature keeps us searching for the right answers, not just the obvious ones.

Courageous

We dare to do what others will not. We know it is the only way we can make a meaningful impact on the lives of those we serve. We will face adversity, but we will not let it keep us from doing what’s right.

Distinctive

We are authentic and stay true to ourselves, without artifice or urge to imitate. We commit ourselves to the development of products and services that only Otsuka could conceive and make a reality.

What We Believe In

Perseverance

We persist to do what’s right and what matters.

Unconventional thinking

We live to create and discover a better way.

Humility

We unite to serve the needs of others before our own.

Our Purpose

Watch this video to see how Otsuka's purpose comes to life.

See our open positions.

CAREERS

News & Media

Learn more about the latest happenings at Otsuka. Select to see US news or read our press releases. You can also stay up to date with our global news in the link below.

Image

Media Contact:

Robert Murphy

Senior Director, External Communications,
Otsuka America Pharmaceutical, Inc

Phone:
609-249-7262
Email:
[email protected]

Featured News

Press Release

Otsuka Announces FDA Plans to Host an Advisory Committee Meeting to Discuss the sNDA for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder (PTSD)

Otsuka America Pharmaceutical, Inc., (OAPI) and Otsuka Pharmaceutical, Co., Ltd. (Otsuka) announce that the U.S. Food and Drug Administration (FDA) plans to host a Psychopharmacologic Drugs Advisory Committee (PDAC) meeting to seek input on issues related to the Supplemental New Drug Application (sNDA) for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD).

January 10, 2025

Read more

All news

Showing:
Global News

Press Release

Sunovion and Otsuka Initiate Clinical Development of Ulotaront for the Treatment of Generalized Anxiety Disorder

Sunovion Pharmaceuticals Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc. today announced that the first patient has been randomized in a Phase 2/3 clinical study evaluating ulotaront, a trace amine-associated receptor 1 (TAAR1) agonist with 5-HT1A agonist activity, for the treatment of generalized anxiety disorder (GAD). In addition to GAD, ulotaront is being investigated in late-stage clinical studies for the treatment of schizophrenia and for the adjunctive treatment of major depressive disorder (MDD).

April 26, 2023

Read more

Press Release

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Alzheimer’s Dementia

Otsuka Pharmaceutical Development & Commercialization, Inc. and Lundbeck Pharmaceuticals LLC announce the Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) met to discuss the supplemental New Drug Application (sNDA) of REXULTI® (brexpiprazole) for the treatment of agitation associated with Alzheimer’s dementia (AAD). The committee voted 9-1 that Otsuka and Lundbeck provided sufficient data to allow the identification of a population in whom the benefits of treating AAD with REXULTI outweigh its risks.

April 16, 2023

Read more

Press Release

Otsuka and Lundbeck Published Study Results Showing Aripiprazole 2-Month, Ready-to-Use, Long-Acting Injectable is as Well-Tolerated, and Provides Similar Plasma Levels as Aripiprazole 1-Month for Treatment of Schizophrenia and Bipolar I Disorder

Otsuka Pharmaceutical Co., Ltd and H. Lundbeck A/S published results from research demonstrating that an investigational long-acting injectable, aripiprazole 2-month, ready-to-use 960 mg, offers comparable tolerability, safety and therapeutic plasma levels as aripiprazole 1-month, ready-to-use 400 mg, currently approved in adult patients for the treatment of schizophrenia or the maintenance treatment of bipolar I disorder (BP-I). The research is published in CNS Drugs.

April 04, 2023

Read more

Discover more mental
health and caregiver
perspectives.

VALUED MINDS NEWS

Working Together

At Otsuka, our dedication to patients, families, and providers drives us to uncover answers to complex, underserved medical needs. We seek to defy limitation and are working to tackle the status quo in the industry and beyond to serve those who need us most. Collaborations are an essential part of this commitment, and we seek to work with companies whose values, commitment, and compassion align with our own.

Photo of business people seated around a conference table with laptops opened.

Our Purpose

Otsuka Business Development: Better health worldwide through external innovation and strategic collaborations.

Why Otsuka?

Otsuka is committed to collaborating with innovators to tackle the unique needs of patients, providers, and caregivers. Our team shares in our collaborators' passion and will dedicate ourselves to understanding their aspirations and desired outcomes.

Our team

When working together in alliances or as affiliates, our Global Business Development team strives to create a culture of empathy that is rooted in our dedication to the areas of focus. Our business development team brings notable experience within the US and abroad, allowing us to build relationships founded on expertise and common goals. They provide the tools and leadership to enable each relationship to reach its maximum value and potential, and are committed to:

Otsuka Holdings Business Development

VISIT SITE

Trust

Develop relationships with collaborators that are built on trust.

Growth

Realize and maximize the spirit and intent of each unique collaboration.

Action

Use a proven, disciplined approach to ensure that collaborations balance rigor and flexibility to support timely decision-making, early detection and mitigation of risk, and effective conflict resolution.

Our Process

We consistently strive to enhance our capabilities and elevate how we might improve patient health. We seek innovations with organizations that allow us to amplify what we all are working toward. Our process involves 3 primary steps:

1

Our Process

We conduct an initial evaluation of any provided non-confidential and public information.

2

Our Process

A joint team from Otsuka and your organization examines confidential information in more detail.

3

Our Process

We lead due diligence efforts and negotiations of deal terms.

Let’s explore how we can work together to improve the lives of patients.

Contact US

What We Are Seeking

In the US, we focus on specific areas with high unmet need where our expertise may allow us to improve health outcomes.

Therapeutic Areas of Interest

Therapeutic Areas of Interest

Therapeutic Areas of Interest

Therapeutic Areas of Interest

Alliances

lundbeck-logo@3x

Lundbeck

Many pharmaceutical companies have experienced challenges when ushering in new central nervous system (CNS) treatments. The Otsuka and Lundbeck global alliance agreement was born in 2011 out of this challenge. Both companies have a shared focus on helping patients with mental health disorders. Lundbeck has a long heritage of innovation in neuroscience, and Otsuka has been focusing research and development efforts on CNS for decades. Through this alliance, Otsuka and Lundbeck have taken an unconventional approach to develop and commercialize 5 psychiatric and neurologic therapies worldwide thus far. Together we are creating a positive impact to help improve the lives of people living with CNS disorders. 

click-logo@3x

Click Therapeutics

With Otsuka’s focus on digital innovation and unconventional thinking, our alliance with Click Therapeutics is a natural step toward developing solutions for patients that go beyond medication. We are working on developing and commercializing a prescription digital therapeutic for treating major depressive disorder (MDD). This alliance combines Click Therapeutics’ specialization in discovering, validating, and deploying software applications with Otsuka’s commitment and expertise in researching, developing, and commercializing treatments for mental illness. Together, we are breaking down barriers and have the potential to transform mental healthcare.

Affiliates

visterra-logo@3x

Visterra

Otsuka acquired Visterra in 2018 to continue developing solutions for unmet needs in nephrology. Visterra is a clinical-stage biotechnology company that is committed to developing innovative antibody-based therapies for patients with kidney diseases and other hard-to-treat conditions. The Visterra pipeline includes programs targeting immunoglobulin A nephropathy and kidney diseases, as well as cancer, chronic pain, and infectious diseases. The extensive overlap in therapeutic focus between our 2 companies, along with a shared culture of creativity and commitment to patients, enables us to tackle the most difficult treatment challenges.

McQuade Center for Strategic Research & Development (MSRD)

McQuade Center for Strategic Research & Development (MSRD)

The McQuade Center for Strategic Research and Development (MSRD) is a US limited-liability company that was started to identify and fund innovative early-stage research and development programs. These programs are the building blocks for future Otsuka products. MSRD is named for Robert McQuade, PhD.

Who We Are

At our core is perseverance–a fierce determination to overcome any obstacle, regardless of setbacks, on behalf of patients, caregivers, and their loved ones. We will not be bound by doing what’s been done before. Instead, we free ourselves from preconceived notions to discover solutions that advance patient care. Our mission is clear. Otsuka-people: creating new products for better health worldwide.

Our Focus

Neuroscience

Our driving philosophy at Otsuka is to serve those with unmet medical needs, and that couldn’t be more true than in our dedication to the central nervous system (CNS) space. In our 30 years of experience working in this therapeutic area, we continue to innovate and defy limitation by taking risks to overcome the complexities of treating mental health. We respect the value within every mind and are committed to making a difference in the lives of patients living with schizophrenia, major depressive disorder, bipolar disorder, anxiety disorders, and other CNS conditions.

Nephrology

Recognizing a critical gap in clinical expertise and research within nephrology, Otsuka took the initiative to pioneer advancements. For decades, we have dedicated ourselves to driving innovation in this field and in others with significant unmet needs. Our commitment remains steadfast in developing groundbreaking therapeutics in nephrology and other areas, revolutionizing treatment possibilities. Through Otsuka’s commitment to enduring perseverance, we have achieved significant breakthroughs, offering renewed hope to patients and expanding treatment options for clinicians, and we will continue to do so.

Discover our pipeline.

RESEARCH

Our Legacy

1921

Busaburo Otsuka founded Otsuka in Tokushima Prefecture, Japan, with an unconventional idea and the belief that anything is possible. Otsuka has been on a journey of creativity and innovation ever since.

1985

The first Otsuka US research and development base was established in Rockville, Maryland. Just a few years later, in 1989, Otsuka’s first US commercial organization was created, Otsuka America Pharmaceutical, Inc (OAPI).

2002

Otsuka’s second US location, in Princeton, New Jersey, was opened. We continued our evolution, and in 2007 Otsuka Pharmaceutical Development & Commercialization, Inc (OPDC), was created to oversee all commercial pharmaceutical and medical device activities in the United States.

2020

Today the two companies, OAPI and OPDC, are part of one family—the Otsuka Holdings Co, Ltd, that has over 180 companies, with more than 45,000 employees in 28 countries around the world.

Discover our latest milestones and future plans in the 2023-2024 Economic and Health Impact Report.

DOWNLOAD REPORT

Our Family of Companies

Our family of companies is committed to offering innovative products that go beyond healthcare to improve the health and well-being of patients. Otsuka America Pharmaceutical, Inc (OAPI) and Otsuka Pharmaceutical Development & Commercialization, Inc (OPDC) belong to a distinguished family of US affiliates.

Subscribe to